Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia

BACKGROUND: Eltrombopag is a thrombopoietin receptor agonist with excellent treatment outcomes in immune thrombocytopenia (ITP). Here, we analyzed the dose of eltrombopag required to achieve and maintain safe platelet counts in Korean ITP patients. METHODS: Adult refractory ITP patients (<30,000...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yeo-Kyeoung, Lee, Seung-Sin, Jeong, Sung-Hoon, Ahn, Jae-Sook, Yang, Deok-Hwan, Lee, Je-Jung, Kim, Hyeoung-Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377333/
https://www.ncbi.nlm.nih.gov/pubmed/25830126
http://dx.doi.org/10.5045/br.2015.50.1.19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377333/
https://www.ncbi.nlm.nih.gov/pubmed/25830126
http://dx.doi.org/10.5045/br.2015.50.1.19

Ejemplares similares